Effect of mepindolol on serum lipids

A. Martignoni, G. Perani, G. Finardi, E. Mastropasqua, R. Fogari

Research output: Contribution to journalArticlepeer-review


In view of the postulated association between plasma lipids and the development of atherosclerosis, there is growing interest in the effects of beta blockers on plasma lipids. This study was undertaken to investigate whether a nonselective beta blocker, such as mepindolol, which possesses intrinsic sympathomimetic activity, causes significant changes in serum lipids, particularly in their distribution among the different lipoproteins. Eighteen healthy subjects, twelve males and six females, were given mepindolol orally, daily doses of 0.2 mg/kg averaging 10-15 mg. Pre- and post-treatment fasting total serum cholesterol, HDL cholesterol, LDL cholesterol, and triglycerides were evaluated; the ratio LDL cholesterol/HDL cholesterol was also calculated. Total cholesterol did not change significantly after treatment with mepindolol (-1.9 mg%), whereas a small and nonsignificant decrease was observed in LDL cholesterol (-6 mg%); no change was found in HDL cholesterol (-0.2 mg%). Serum triglycerides showed a significant increase (+20.9 mg%, p

Original languageEnglish
Pages (from-to)543-545
Number of pages3
JournalInternational Journal of Clinical Pharmacology Therapy and Toxicology
Issue number11
Publication statusPublished - 1982

ASJC Scopus subject areas

  • Toxicology
  • Pharmacology (medical)


Dive into the research topics of 'Effect of mepindolol on serum lipids'. Together they form a unique fingerprint.

Cite this